BiOrion is a Dutch clinical stage biopharmaceutical company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. We are currently developing a PET-imaging diagnostic for NASH/liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for metastatic colon cancer. Our platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides and VHH nanobodies.

Read more


Fibrotic tissue, as present in liver fibrosis and in mesenchymal type colon cancer stroma, is characterized by abundant myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of antifibrotic drugs, thereby leaving healthy tissues unaffected. After binding of BiOrion’s peptide-conjugate to the receptor, the complex is internalized and accumulated rapidly and, dependent on the payload, can exert its intracellular effect.

Read more


BiOrion has two active development programs. In the non-invasive diagnostic PET imaging program, radioactive Gallium-68 is conjugated to BOT501, the molecule containing the receptor-binding peptide. This PET imaging diagnostic is developed to identify patients with liver fibrosis or mesenchymal subtype colon cancer and to monitor therapy. In the radiotherapeutic program, radioactive Lutetium-177 is replacing radioactive Gallium-68 in BOT501. This radiotherapeutic is developed to treat patients with advanced metastatic mesenchymal subtype colon cancer.

Read more

Selective Targeting of Fibrotic stroma

allowing precise PET radio-imaging and radiotherapy of mesenchymal type colon cancer


More News >>


no event